Felixvet Introduces Praziquantel Tablets 23 mg for the Removal of Tapeworm Infections in Cats

Kansas City, Mo. — July 16, 2026 — Felixvet Inc. today announced the commercial availability of Praziquantel Tablets 23 mg, an FDA-approved feline cestocide indicated for the removal of Dipylidium caninum and Taenia taeniaeformis tapeworm infections in cats. Approved by the U.S. Food and Drug Administration on December 22, 2025, under ANADA 200-834, the product expands Felixvet’s growing portfolio of companion animal pharmaceuticals and provides veterinarians with an important treatment option for managing common feline tapeworm infections.

Product Details

“We’re excited to bring Praziquantel Tablets 23 mg to the veterinary market and expand access to an important treatment option for feline patients,” said Lauren Landolph, Vice President, Commercial Strategy & Distribution Channels, Felixvet. “Tapeworm infections remain a common concern in cats, and this approval provides veterinarians and pet owners with an FDA-approved chewable tablet designed to support effective treatment and ease of administration.”

Praziquantel Tablets 23 mg are indicated for the removal of Dipylidium caninum and Taenia taeniaeformis, two of the most commonly encountered tapeworm species affecting cats. The product is sized for easy oral administration and may be administered directly or crumbled and mixed with food. 

The product is therapeutically equivalent to the pioneer drug and provides the same safety and efficacy profile. Praziquantel Tablets are available in a single 23 mg strength and feature a palatable beef flavor. Each chewable tablet is scored to support easy and accurate dosing. 

Praziquantel Tablets 23 mg are available in:

• 3-count chewable tablet bottles 
• 50-count chewable tablet bottles 
• 150-count chewable tablet bottles 

“At Felixvet, we’re committed to providing veterinarians with trusted treatment options across a broad range of therapeutic categories,” added Lauren Landolph. “The addition of Praziquantel Tablets 23 mg reflects our continued focus on expanding access to high-quality products that support the health and well-being of companion animals.”

Felixvet continues to expand its portfolio of FDA-approved companion animal pharmaceuticals, supporting veterinarians and pet owners with high-quality, bioequivalent treatment options across companion animal medicine.

For additional information, please contact info@felixvet.com

About Felixvet

Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix develops and commercializes high-quality, bioequivalent pharmaceutical products for companion animals. The company is focused on expanding access to FDA-approved veterinary medicines through a growing portfolio of trusted treatment options for veterinarians and pet owners.

Media Contact

Paula Flavin
Project Marketing Manager, US Operations
D: 816-912-2000
E: info@felixvet.com